Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 183

1.

[High doses of immunoglobulin G in the therapy for severe forms of myasthenia gravis and Guillain-Barré syndrome].

Lavrnić D, Romić M, Kacar A, Stojanović-Rakocević V, Stević Z, Vujić A, Basta I, Marjanović I, Bogdanović G, Apostolski S.

Vojnosanit Pregl. 2006 Jan;63(1):37-42. Serbian.

PMID:
16471247
2.

Combined Guillain-Barré syndrome and myasthenia gravis.

Hsieh MY, Chan OW, Lin JJ, Lin KL, Hsia SH, Wang HS, Chiu CH.

Brain Dev. 2013 Oct;35(9):865-9. doi: 10.1016/j.braindev.2012.10.016. Epub 2012 Nov 22.

PMID:
23177060
3.

Human Immunoglobulin Versus Plasmapheresis in Guillain-Barre Syndrome and Myasthenia Gravis: A Meta-Analysis.

Ortiz-Salas P, Velez-Van-Meerbeke A, Galvis-Gomez CA, Rodriguez Q JH.

J Clin Neuromuscul Dis. 2016 Sep;18(1):1-11. doi: 10.1097/CND.0000000000000119.

PMID:
27552383
4.
5.

Immunoadsorption in Guillain-Barré syndrome and myasthenia gravis.

Haupt WF, Rosenow F, van der Ven C, Birkmann C.

Ther Apher. 2000 Jun;4(3):195-7. Review.

PMID:
10910018
6.

Prominent plasmacytosis following intravenous immunoglobulin correlates with clinical improvement in Guillain-Barré syndrome.

Mori I, Parizot C, Dorgham K, Demeret S, Amoura Z, Bolgert F, Gorochov G.

PLoS One. 2008 May 7;3(5):e2109. doi: 10.1371/journal.pone.0002109.

7.

[Plasmapheresis in neurological diseases. Experience in 140 procedures in 47 patients].

Nogales-Gaete J, Valenzuela D, Liendo F, Vidal P, Gil G, Sáez D.

Rev Med Chil. 2004 Mar;132(3):295-8. Spanish.

PMID:
15376565
8.

Efficacy of Intravenous Immunoglobulin in Neurological Diseases.

Lünemann JD, Quast I, Dalakas MC.

Neurotherapeutics. 2016 Jan;13(1):34-46. doi: 10.1007/s13311-015-0391-5. Review.

9.

Intravenous immunoglobulin for myasthenia gravis.

Gajdos P, Chevret S, Toyka K.

Cochrane Database Syst Rev. 2008 Jan 23;(1):CD002277. doi: 10.1002/14651858.CD002277.pub3. Review. Update in: Cochrane Database Syst Rev. 2012;12:CD002277.

PMID:
18254004
10.

[Treatment of myasthenia gravis with intravenous immunoglobulin G (IVIG)].

Lavrnić DB, Stojanović V, Marinković Z, Pavlović S, Vidaković A, Apostolski S.

Srp Arh Celok Lek. 1995 May-Jun;123(5-6):146-8. Serbian.

PMID:
17974459
11.

Intravenous immunoglobulin for myasthenia gravis.

Gajdos P, Chevret S, Toyka KV.

Cochrane Database Syst Rev. 2012 Dec 12;12:CD002277. doi: 10.1002/14651858.CD002277.pub4. Review.

PMID:
23235588
12.

Intravenous immunoglobulin for Guillain-Barré syndrome.

Hughes RA, Raphaël JC, Swan AV, van Doorn PA.

Cochrane Database Syst Rev. 2001;(2):CD002063. Review. Update in: Cochrane Database Syst Rev. 2004;(1):CD002063.

PMID:
11406030
13.

Therapeutic plasma exchange in patients with neurologic diseases: retrospective multicenter study.

Kaynar L, Altuntas F, Aydogdu I, Turgut B, Kocyigit I, Hacioglu SK, Ismailogullari S, Turgut N, Erkurt MA, Sari I, Oztekin M, Solmaz M, Eser B, Ersoy AO, Unal A, Cetin M.

Transfus Apher Sci. 2008 Apr;38(2):109-15. doi: 10.1016/j.transci.2007.11.002. Epub 2008 Mar 10.

PMID:
18331814
14.

Plasma exchange after initial intravenous immunoglobulin treatment in Guillain-Barré syndrome: critical reassessment of effectiveness and cost-efficiency.

Oczko-Walker M, Manousakis G, Wang S, Malter JS, Waclawik AJ.

J Clin Neuromuscul Dis. 2010 Dec;12(2):55-61. doi: 10.1097/CND.0b013e3181f3dbbf.

PMID:
21386771
15.

The role of immunotherapy in Guillain-Barré syndrome: understanding the mechanism of action.

Shahrizaila N, Yuki N.

Expert Opin Pharmacother. 2011 Jul;12(10):1551-60. doi: 10.1517/14656566.2011.564160. Epub 2011 Apr 7. Review.

PMID:
21473704
16.

IgG Fc N-glycosylation in Guillain-Barré syndrome treated with immunoglobulins.

Fokkink WJ, Selman MH, Dortland JR, Durmuş B, Kuitwaard K, Huizinga R, van Rijs W, Tio-Gillen AP, van Doorn PA, Deelder AM, Wuhrer M, Jacobs BC.

J Proteome Res. 2014 Mar 7;13(3):1722-30. doi: 10.1021/pr401213z. Epub 2014 Feb 17.

PMID:
24533874
17.

Is a second cycle of immunoglobulin justified in axonal forms of Guillain-Barré syndrome?

Godoy DA, Rabinstein A.

Arq Neuropsiquiatr. 2015 Oct;73(10):848-51. doi: 10.1590/0004-282X20150136.

18.

Intravenous immunoglobulin therapy for Guillain-Barré syndrome with IgG anti-GM1 antibody.

Kuwabara S, Mori M, Ogawara K, Hattori T, Oda S, Koga M, Yuki N.

Muscle Nerve. 2001 Jan;24(1):54-8.

PMID:
11150966
19.

Selective immune adsorption treatment of severe Guillain Barré syndrome in the intensive care unit.

Galldiks N, Dohmen C, Neveling M, Fink GR, Haupt WF.

Neurocrit Care. 2009 Dec;11(3):317-21. doi: 10.1007/s12028-009-9252-6.

PMID:
19642026
20.

Intravenous immunoglobulin for Guillain-Barré syndrome.

Hughes RA, Swan AV, van Doorn PA.

Cochrane Database Syst Rev. 2010 Jun 16;(6):CD002063. doi: 10.1002/14651858.CD002063.pub4. Review. Update in: Cochrane Database Syst Rev. 2012;7:CD002063.

PMID:
20556755

Supplemental Content

Support Center